News Release 

Nature publishes review article heralding multispecific drugs as the next wave of drug discovery

Multispecifics could pave the way for potential new treatments aimed at disease targets currently viewed as 'undruggable'

Amgen

In the article "Multispecific drugs herald a new era of biopharmaceutical innovation" published today in Nature, Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen, discusses how the advent of multispecific drugs is leading the next revolution of drug discovery and development. In the review, Deshaies describes the major classes of multispecific drugs and how they work, provides a perspective on what the future holds, and discusses challenges that must be overcome to make the coming wave of transformative innovation a reality.

Instead of engaging targets on their own like conventional medicines, one class of multispecific drugs tethers the active agent at its intended site of action, whereas a second class mobilizes biological mechanisms to do the heavy lifting. These latter agents bring two things together, like a molecular matchmaker. On one end the drug binds to the target to be altered (inhibited, activated or destroyed) and the other end binds to the cellular effector that acts on the target. Matchmaker multispecific drugs have the potential to target the 85% of proteins currently thought of as "undruggable."

"In the future medicines could function very differently than conventional medicines do today. In biopharma pipelines across the industry, we're seeing more and more multispecific drugs that can form connections with two or more proteins," said Deshaies. "They include some highly sophisticated structures that function as molecular matchmakers. By inducing proximity between their targets and natural enzymes or even cells, multispecifics can harness the awesome power of biology to go well beyond what conventional drugs can accomplish. This isn't an incremental improvement in drug design, it's a sea change."

There are many versatile natural mechanisms that induced proximity medicines can use to fight disease when matched with the right target, and Amgen is at the forefront with its Bispecific T-cell engager (BiTE®) molecules and Induced Proximity Platform (IPP). Approximately two-thirds of Amgen's pipeline molecules through Phase 1 are multispecifics.

###

Amgen has experience building highly promising platform technologies. In 2012, Amgen acquired Micromet, which pioneered the BiTE® technology platform to develop BiTE® molecules. BiTE® molecules work by inducing proximity at the cellular level by bringing T cells together with tumor cells so the T cells can recognize and destroy the tumor cells. Amgen is exploring other areas of induced proximity including PROTAC® (proteolysis targeting chimeras) molecules, which leverage the enzymes that tag unwanted or damaged proteins for destruction by a molecular machine called the proteasome.

Visit http://www.AmgenScience.com to read an editorial by Dr. Deshaies and learn more about Amgen's approach to multispecific medicines with the IPP.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit http://www.amgen.com and follow us on http://www.twitter.com/amgen.

Amgen Forward-Looking Statements

This communication contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration's ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla® (apremilast) acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.